Abcam, ab223498, Anti-CTAG1B antibody [SP349]

Size: 100µL / 500µL / 1mL
Rabbit Recombinant Monoclonal CTAG1B antibody. Suitable for Flow Cyt, WB, IHC-P and reacts with Human samples. Cited in 2 publications.
Key facts
Host species:Rabbit,
Clonality:Monoclonal,
Clone number:SP349,
Isotype:IgG,
Carrier free:No,
Reacts with:Human,
Applications:IHC-P, Flow Cyt, WBSee reactivity dataSee the reactivity data table below for information on validated species and application combinations.,
Immunogen:The exact immunogen used to generate this antibody is proprietary information.

Properties and Storage Information:
Form-Liquid, Purification technique-Affinity purification Protein A/G, Storage buffer-pH: 7.6Preservative: 0.1% Sodium azideConstituents: PBS, 1% BSA, Shipped at conditions-Blue Ice, Appropriate short-term storage duration-1-2 weeks, Appropriate short-term storage conditions-+4°C, Appropriate long-term storage conditions--20°C, Aliquoting information-Upon delivery aliquot, Storage information-Avoid freeze / thaw cycle

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
CTAG1B also known as NY-ESO-1 is a cancer/testis antigen with an approximate molecular mass of 22 kDa. This protein is absent in most normal tissues but shows expression in the testes and a variety of tumors. CTAG1B is recognized for its potential role in immune targeting due to its restricted expression profile. The protein plays a part in antigenic presentation and stimulates T-cell response making it a significant focus for cancer immunotherapy research.
Biological function summary
CTAG1B is involved in the immune response against tumors. It is part of the group called cancer/testis antigens due to its low expression in normal tissues except the testes. This restricted pattern allows CTAG1B to function in distinguishing between tumor and normal cells which is important for targeted therapies. It does not belong to a specific multiprotein complex but contributes to immune recognition by presenting as an antigenic determinant.
Pathways
CTAG1B engages predominantly in cellular processes associated with the immune system's adaptive arm. It plays a role in the antigen processing and presentation pathway where it functions to engage CD8+ T cells. The protein associates with other antigens expressed in cancer such as MAGE-A1 in enabling an immune response against tumor cells. By acting alongside these proteins CTAG1B supports pathways leading to the recognition and destruction of malignant cells.
CTAG1B shows a strong connection to cancer particularly in melanoma and ovarian cancer. It is considered a biomarker for these cancers due to its restricted expression and detection in tumor tissues. In cancer CTAG1B interacts with immune checkpoint proteins such as PD-L1 where it helps sustain and enhance immune responses. This relationship has made CTAG1B a promising target in immunotherapy aiming to improve cancer treatment outcomes.